Atracurium

Atracurium (BW-33A free acid) is a potent, competitive, non-depolarizing neuromuscular blocking agent and an AChR receptor antagonist. It induces bronchoconstriction and neuromuscular blockade, in addition to promoting astroglial differentiation [1] [2] [3] [4] [5].

Atracurium besylate (51W89) is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant for intravenous administration.

DL-Laudanosine (Laudanosine) is a recognized metabolite of atracurium and cisatracurium.

(S)-Laudanosine, the (S) enantiomer of laudanosine, emerges as a metabolite from the neuromuscular blocking agents atracurium and cisatracurium. It functions by inhibiting prolyl endopeptidase and obstructing arachidonic acid- and collagen-induced aggregation in washed rabbit platelets.